JenniferRDiamondMD

Breast Cancer, Hematologic Oncology

Co-Director, Women's Cancer Developmental Therapeutics Program Breast Oncology and Phase I Programs Associate Professor, Medicine, University of Colorado Anschutz Medical Campus

Join to view full profile

Dr. Diamond is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Diamond's full profile

Already have an account?

Office
1635 Aurora Ct
Aurora, CO 80045
Phone+1 720-848-0000

Fax+1 720-848-6802

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2010
University of ColoradoResidency, Internal Medicine, 2004 - 2007
University of Arizona College of MedicineClass of 2004

Certifications & Licensure

CO State Medical License 2007 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Start of enrollment: 2012 Jul 01
Completed
Phase 2
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
A Study of OKI-179 in Patients With Solid Tumors Start of enrollment: 2019 May 08
Completed
Phase 1
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors Start of enrollment: 2021 Sep 07
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.
Anthony D Elias, Alyse W Staley, Monica Fornier, Gregory A Vidal, Vida Alami
NPJ Breast Cancer. 2024-10-06
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
S Lindsey Davis, Wells A Messersmith, W Thomas Purcell, Elaine T Lam, Bradley R Corr
Cancers. 2024-04-10
2 citations
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Stephen G Smoots, Anna R Schreiber, Marilyn M Jackson, Stacey M Bagby, Adrian T A Dominguez
Breast Cancer Research. 2024-03-01

Press Mentions

OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical OfficerOctober 14th, 2021
Increase in Cancer Deaths Predicted Due to COVID-19 PandemicDecember 22nd, 2020
OnKure and CU Cancer Center Announce First Patient Enrolled in Clinical Trial of OKI-179, a Potent and Selective HDAC InhibitorJune 17th, 2019
Join now to see all